Pharmacogenomics-Supported Psychotropic Prescribing Trial

NARecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2030

Conditions
Mental DisorderPharmacogeneticsAdverse Drug Reaction (ADR)Effectiveness
Interventions
DIAGNOSTIC_TEST

Pharmacogenetic Testing

Participants will donate a 1ml (one-fifth of a teaspoon) sample of saliva. DNA extracted from the saliva sample will be used for genotyping. Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) and delivered to the treating physician for use in their clinical decision-making. The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the patient's current and future care.

Trial Locations (2)

R3C 3H8

NOT_YET_RECRUITING

Shared Health Facilities, Winnipeg

R3E 0T5

RECRUITING

University of Manitoba College of Pharmacy, Winnipeg

All Listed Sponsors
collaborator

University of Calgary

OTHER

collaborator

Shared Health Manitoba

UNKNOWN

collaborator

Winnipeg Regional Health Authority

OTHER

collaborator

Health Sciences Centre, Winnipeg, Manitoba

OTHER

lead

University of Manitoba

OTHER